News

Brief news reports on Tuberculosis

Immune Network to start clinical trial of оral mycobacterium vaccae in tuberculosis patients

VANCOUVER, British Columbia, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd. reports that its business partner Immunitor company has launched a Phase 2 clinical trial of a novel anti-tuberculosis immunotherapy consisting of orally-delivered, heat-inactivated Mycobacterium vaccae. The new tableted preparation was formulated according to clinically validated proprietary technology developed by Immunitor company.

Read More →

UNITAID seeking letters of intent to promote uptake of diagnostic technologies

Following a decision by its Board, UNITAID has issued a call for letters of intent on the topic of diagnostics for HIV, tuberculosis and malaria.

Read More →

Marker found for predisposition to tuberculosis

Scientists believe they have found a marker indicating genetic predisposition to tuberculosis, bringing closer the day when doctors can adjust therapies to individuals based on their genotype. Two mutations in an immune system gene called TLR1 are responsible for cellular changes that bring resistance to TB, according to research presented in the Journal of Leukocyte Biology.

Read More →

Few HIV patients tested for TB

Only 1 percent of HIV-positive patients worldwide have been tested for tuberculosis, a curable infection that frequently kills those living with AIDS.

Read More →

Towards lab-free tuberculosis diagnosis

Tuberculosis (TB), fuelled in part by the HIV epidemic, remains a major challenge to public health. Despite the potential for most cases of tuberculosis to be curable, TB causes around two million deaths per annum. These deaths are in part due to late or missed diagnosis. Improving the performance of diagnostics and their availability are key to reducing global morbidity and mortality.

Read More →

New WHO guidelines call for more evidence on drug-resistant TB

The European Respiratory Journal is today (04 August 2011) publishing the updated guidelines of the World Health Organization (WHO) that aim to help manage drug-resistant tuberculosis (TB).

Read More →

An advance toward an “electronic nose” urine test for TB

Read More →

TB medicines are now part of the South African drug tender process

Health officials have negotiated 18% price cuts with suppliers of antibiotics and tuberculosis drugs, saving R242m over two years. [Read the story on Business Day.](http://www.businessday.co.za/articles/Content.aspx?id=150055 "State secures big savings on drug prices")

Read More →

UH Case Medical Center to commence Phase 1 clinical trial on TMC207

University Hospitals (UH) Case Medical Center will begin a Phase 1 clinical trial on a new experimental anti-tuberculosis drug called TMC207. This drug represents the first new class of anti-TB drugs in the past 60 years and it has activity against both drug-susceptible and drug-resistant TB.

Read More →

New TB drug-resistance test shows promise but needs investment for those diagnosed to be cured

Two research studies in this week's PLoS Medicine suggest that a new automated DNA test for tuberculosis (Xpert MTB/RIF), which can detect TB within 2 hours and has been endorsed by the World Health Organization, can significantly increase TB detection rate compared to other tests, particularly in HIV positive patients who have a high risk of being infected with TB, including multidrug resistant TB. An accompanying Essay and Perspective highlight the economic challenges and implications of such diagnostic tests.

Read More →

Page 546 of 547 · Total posts: 10

←First 545 546 547 Last→